Boston Scientific Launches Drug Eluting Stent Solution to Treat Severe Lesions Below the Knee

Natick, Massachusetts (ots/PRNewswire) - Innovative Stent Solution to treat patients with Critical Limb Ischemia

Boston Scientific has launched in European countries the PROMUS ELEMENT(TM) PLUS BTK (Below The Knee) Everolimus-Eluting Stent System for the treatment of certain severe peripheral artery lesions. The Drug Eluting Stent (DES) has CE Mark approval for both Monorail and Over-The-Wire versions and will be available immediately.

PROMUS ELEMENT(TM) PLUS BTK is indicated for the treatment of Critical Limb Ischemia (CLI) or severe lower leg claudication in infrapopliteal lesions. Critical Limb Ischemia is a severe obstruction of the arteries which markedly reduces blood flow to the extremities (in most cases feet and legs) and has progressed to the point of severe pain at rest, non-healing wounds or gangrene. CLI appears in about 500 to 1,000 new cases per million people every year in Europe. This highly debilitating disease is usually caused by obstructive atherosclerotic arterial disease and is associated with a very high morbidity and mortality risk.

In patients with CLI, restoring and maintaining maximum blood flow to the legs is critical to helping reduce the risk of limb amputation. Stand-alone Percutaneous Transluminal Angioplasty (PTA), the current standard for treatment of Below-The-Knee arterial disease, is often not enough to keep blood vessels open due to complications that can re-occlude the vessel. These complications are often treated with bare metal stents. Several randomized controlled clinical trials have demonstrated that Drug Eluting Stents have significantly better clinical outcomes than bare metal stents in CLI patients. The prognosis of CLI patients treated with bare metal stents is poor with only 50 percent of patients remaining alive and free from major amputation one year after the diagnosis is made.

"The drug eluting stent is an important additional tool that I use to address focal stenosis in the arteries below the knee, and ultimately reduced amputation rates in CLI and claudicant patients," said Martin Kamarád, M.D., of Podlesí Hospital in Trinec, Czech Republic. "In addition to the benefits of drug delivery I believe the PROMUS ELEMENT(TM) PLUS BTK Stent offers significant advantages in terms of properties in the design and higher resistance to compression and less recoil thanks to its unique Platinum-Chromium alloy and stent architecture."

The Everolimus drug and polymer used on the PROMUS ELEMENT(TM) PLUS BTK Stent have been studied in multiple coronary randomized clinical trials and registries such as the Promus Platinum clinical program involving more than 1800 patients with two years follow-up. In addition, the Platinum Chromium alloy, designed specifically for stenting, enables enhanced visibility and excellent conformability together with less recoil and higher radial strength.

"Thanks to our vast experience with coronary DES, which was transferred and adapted to this specific technology to treat Peripheral Artery Disease (PAD), we can now provide physicians an approved DES device to address PAD challenges," said Jeff Mirviss, President, Peripheral Interventions Division at Boston Scientific. "We are extremely proud to offer this purpose-built device for patients with PAD."

PROMUS ELEMENT(TM) PLUS BTK is currently available in both Over-The-Wire and Monorail versions, offering physicians the flexibility to select their technical preference. It also offers an advanced low-profile delivery system designed to facilitate precise stent placement across challenging lesions.

For more news about Boston Scientific please follow us on Twitter @bsc_eu_heart (

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Digital press kit:

Rückfragen & Kontakt:

Simonetta Balbi, PR and Corporate Communication EMEA,
Boston Scientific, +39-3387936422 (mobile), +39-0106060281 (direct), ; Steven Campanini, +1-508-652-5740 (office), Media
Relations, Boston Scientific Corporation, ;
Michael Campbell, +1-508-650-8023 (office), Investor Relations,
Scientific Corporation,